文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

基线血浆IL-18可能预测ARDS患者对辛伐他汀的治疗反应:HARP-2随机临床试验的二次分析

Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial.
PubMed 文献 · Crit Care · 2022-06-07
一句话结论在基线血浆IL-18≥800 pg/ml的ARDS患者中,辛伐他汀组28天死亡率24.0%,安慰剂组36.8%(p=0.01);高IL-18与28天死亡率升高相关(HR 1.89)。

本文为HARP-2随机临床试验的二次分析,纳入511例有基线血浆IL-18数据的ARDS患者,按基线IL-18水平比较28天死亡率及对辛伐他汀的反应。结果显示高基线血浆IL-18(≥800 pg/ml)与28天死亡率升高相关(高IL-18组30.6% vs 低IL-18组17.5%;HR 1.89 [95% CI 1.30-2.73];p=0.001)。在高基线血浆IL-18患者中,分配至辛伐他汀组者28天死亡概率低于安慰剂组(24.0% vs 36.8%;p=0.01)。体外实验中,辛伐他汀(而非瑞舒伐他汀)可减少刺激后巨噬细胞分泌IL-18和IL-1β。作者认为基线血浆IL-18可能有助于识别可从辛伐他汀治疗中获益的ARDS患者。

要点

  • 基线血浆IL-18≥800 pg/ml的ARDS患者28天死亡率30.6%,低于该阈值者17.5%,HR 1.89(95% CI 1.30-2.73),p=0.001。
  • 高基线血浆IL-18(≥800 pg/ml)患者中,辛伐他汀组28天死亡率24.0%,安慰剂组36.8%,p=0.01。
  • 体外实验中,辛伐他汀(而非瑞舒伐他汀)减少ATP与LPS刺激后巨噬细胞分泌IL-18和IL-1β。
  • 作者认为基线血浆IL-18可能用于识别可从辛伐他汀治疗中获益的ARDS患者,实现个体化治疗。

适用人群与场景

  • HARP-2随机临床试验中有基线血浆IL-18数据的ARDS患者511例(二次分析人群)。

诊断标准与关键阈值

  • 基线血浆IL-18以≥800 pg/ml定义为高IL-18。

研究设计与关键结果

  • 研究类型:HARP-2随机临床试验的二次分析,共511例有可用数据的ARDS患者。
  • 高基线血浆IL-18(≥800 pg/ml)与28天死亡率升高相关:高IL-18组30.6% vs 低IL-18组17.5%;HR 1.89(95% CI 1.30-2.73);p=0.001。
  • 高基线血浆IL-18患者中,辛伐他汀组28天死亡概率低于安慰剂组:24.0% vs 36.8%;p=0.01。
  • 体外实验:健康志愿者单核细胞来源巨噬细胞经辛伐他汀或瑞舒伐他汀预孵育后,以ATP和LPS刺激;辛伐他汀(而非瑞舒伐他汀)减少刺激后巨噬细胞分泌IL-18和IL-1β。

证据类型、等级与局限

  • 证据类型:随机临床试验(HARP-2)的二次分析及体外实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为基线血浆IL-18可能通过识别可从辛伐他汀治疗中获益的ARDS患者,实现个体化治疗。
  • 在高基线血浆IL-18(≥800 pg/ml)的ARDS患者中,辛伐他汀与28天死亡概率降低相关(24.0% vs 36.8%;p=0.01)。

指南或共识出处

  • HARP-2随机临床试验(原文为二次分析来源)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Interleukin (IL)-18 is a marker of inflammasome activation, and high baseline plasma IL-18 is associated with increased mortality in patients with sepsis-induced ARDS. The aim of this analysis was to determine if simvastatin was associated with benefit in patients with ARDS and high plasma IL-18.

METHODS: In this secondary analysis of the HARP-2 study, we compared 28-day mortality and response to simvastatin according to baseline plasma IL-18 using cox proportional hazards analysis. Separately, monocyte-derived macrophages from healthy volunteers were pre-incubated with simvastatin or rosuvastatin before stimulation with ATP and LPS, and the effect on secreted IL-18 and IL-1β compared.

RESULTS: 511 patients from HARP-2 had available data. High baseline plasma IL-18 (≥ 800 pg/ml) was associated with increased 28-day mortality (high IL-18 30.6% vs. low IL-18 17.5%; HR 1.89 [95% CI 1.30-2.73]; p = 0.001). Allocation to simvastatin in patients with high baseline plasma IL-18 was associated with a lower probability of 28-day mortality compared with placebo (24.0% vs 36.8%; p = 0.01). Finally, simvastatin, but not rosuvastatin, reduced stimulated macrophage secretion of IL-18 and IL-1β.

CONCLUSION: In patients with high baseline plasma IL-18, simvastatin is associated with a higher probability of survival, and this effect may be due to reduced inflammasome activation. These data suggest that baseline plasma IL-18 may allow a personalised treatment approach by identifying patients with ARDS who could benefit from simvastatin therapy.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Boyle AJ, Ferris P, Bradbury I, et al. Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial. Crit Care. 2022. PMID: 35672834. doi:10.1186/s13054-022-04025-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。